Calcifediol monohydrate |
| Catalog No.GC16720 |
Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate; 25(OH)D3) is a potent ligand for the vitamin D receptor (VDR) with gene regulatory and anti-proliferative properties, and functions as a vitamin D supplement and a VDR antagonist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 63283-36-3
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
Calcifediol monohydrate (25-hydroxy Vitamin D3 monohydrate; 25(OH)D3) is a potent ligand for the vitamin D receptor (VDR) with gene regulatory and anti-proliferative properties, and functions as a vitamin D supplement and a VDR antagonist. As a precursor hormone in the vitamin D endocrine system (VDES), calcifediol undergoes hydroxylation in the liver to form the active hormone, calcitriol. This form of vitamin D can rapidly increase serum vitamin D levels [1-3].
Calcifediol monohydrate (100nM; 24h) decreased amyloid-β (Aβ)-production and increased Aβ-degradation in neuroblastoma cells. Effects were mediated by affecting the Aβ-producing enzymes BACE1 and γ-secretase [4]. Calcifediol monohydrate(10−5M) can induce a rapid increase in Ca2+ levels in hADMSCs cells in vitro [5].
Calcifediol monohydrate (5µg/kg, 100µL; 7 times; i.p)significantly protected mice against DNCB-induced AD. Calcifediol monohydrate may reduce inflammatory cell infiltration and chemokines by inhibiting the phosphorylation of STAT3 and may restore skin barrier function through the downregulation of AQP3 protein expression and inhibition of cell proliferation in In AD mouse model [6]. After viral attack, mice supplemented with Calcifediol monohydrate(125mg/kg; p.o; 7 weeks) stimulated the production of both anti-inflammatory and pro-inflammatory cytokines [7].
References:
[1]. Castoldi A, Herr C, et,al. Calcifediol-loaded liposomes for local treatment of pulmonary bacterial infections. Eur J Pharm Biopharm. 2017 Sep;118:62-67. doi: 10.1016/j.ejpb.2016.11.026. Epub 2016 Nov 22. PMID: 27888144.
[2]. Zheng W, Duan B, et,al. Vitamin D-induced vitamin D receptor expression induces tamoxifen sensitivity in MCF-7 stem cells via suppression of Wnt/β-catenin signaling. Biosci Rep. 2018 Dec 7;38(6):BSR20180595. doi: 10.1042/BSR20180595. PMID: 30314996; PMCID: PMC6435469.
[3]. Lou YR, Molnár F, Peräkylä M, Qiao S, Kalueff AV, St-Arnaud R, Carlberg C, Tuohimaa P. 25-Hydroxyvitamin D(3) is an agonistic vitamin D receptor ligand. J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):162-70. doi: 10.1016/j.jsbmb.2009.11.011. Epub 2009 Nov 26. PMID: 19944755.
[4]. Grimm MOW, Thiel A, Lauer AA, Winkler J, Lehmann J, Regner L, Nelke C, Janitschke D, Benoist C, Streidenberger O, Stötzel H, Endres K, Herr C, Beisswenger C, Grimm HS, Bals R, Lammert F, Hartmann T. Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation. Int J Mol Sci. 2017 Dec 19;18(12):2764. doi: 10.3390/ijms18122764. PMID: 29257109; PMCID: PMC5751363.
[5]. Donati S, Palmini G, Romagnoli C, Aurilia C, Miglietta F, Falsetti I, Marini F, Zonefrati R, Galli G, Marcucci G, Iantomasi T, Brandi ML. In Vitro Non-Genomic Effects of Calcifediol on Human Preosteoblastic Cells. Nutrients. 2021 Nov 25;13(12):4227. doi: 10.3390/nu13124227. PMID: 34959778; PMCID: PMC8707877.
[6]. Lu R, Peng Z, Lian P, Wazir J, Gu C, Ma C, Wei L, Li L, Pu W, Liu J, Wang H, Su Z. Vitamin D attenuates DNCB-induced atopic dermatitis-like skin lesions by inhibiting immune response and restoring skin barrier function. Int Immunopharmacol. 2023 Sep;122:110558. doi: 10.1016/j.intimp.2023.110558. Epub 2023 Jun 30. PMID: 37393836.
[7]. Hayashi H, Okamatsu M, et,al. Oral Supplementation of the Vitamin D Metabolite 25(OH)D3 Against Influenza Virus Infection in Mice. Nutrients. 2020 Jul 5;12(7):2000. doi: 10.3390/nu12072000. PMID: 32635656; PMCID: PMC7400405.
| Cell experiment [1]: | |
|
Cell lines |
Neuroblastoma cells |
|
Preparation Method |
Cells were treated with Calcifediol monohydrate in a final concentration of 100nM or solvent control (EtOH). |
|
Reaction Conditions |
100nM; 24h |
|
Applications |
Calcifediol monohydrate decreased amyloid-β (Aβ)-production and increased Aβ-degradation in neuroblastoma cells. |
| Animal experiment [2]: | |
|
Animal models |
Atopic dermatitis (AD) mice model (Female BALB/c mice) |
|
Preparation Method |
The AD mice model was induced by using DNCB. 1% DNCB was applied once a day to the ears (5μL) of AD-induced mice on days 6, 10, 14, and 18. The treatment was started on the day of challenge (day 6) with an intraperitoneal injection of 100µL Calcifediol monohydrate(5µg/kg). Each dose was given once every two days for a total of seven doses. |
|
Dosage form |
5µg/kg, 100µL; 7 times; i.p |
|
Applications |
Calcifediol monohydrate treatment reduces inflammatory infiltration and edema in the ears of AD mice. |
|
References: |
|
| Cas No. | 63283-36-3 | SDF | |
| Chemical Name | (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol;hydrate | ||
| Canonical SMILES | CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C.O | ||
| Formula | C27H46O3 | M.Wt | 418.65 |
| Solubility | DMSO : 50 mg/mL (119.43 mM);Soluble in Chloroform | Storage | Store at -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3886 mL | 11.9432 mL | 23.8863 mL |
| 5 mM | 0.4777 mL | 2.3886 mL | 4.7773 mL |
| 10 mM | 0.2389 mL | 1.1943 mL | 2.3886 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *